|
Gyros will launch Gyrolab Bioaffy during the upcoming Drug Discovery and Technology meeting, starting August 11 at the Hynes Convention Center,
Boston, U.S.A.
Gyrolab Bioaffy, a CD microlaboratory, together with an updated
Gyrolab Workstation with laser-induced fluorescence detection,
allows scientists to run established sandwich-based immunoassays for
protein quantification at nanoliter scale.
Proteins can be assayed in a format optimized for working with small
volumes and many samples. Nanoliter scale procedures will give a
major reduction in sample and reagent consumption per data point.
Time-consuming and costly investigations caused by limited
availability of sample, such as biomarker profiling in small animal
models, can be reduced to days rather than weeks with more proteins
being assayed in a single sample.
Quantification of cytokines and latest results from this new CD
microlaboratory will be presented at a technology workshop in Room
310, Hynes Convention Center, at 4.30 pm on Tuesday, August 12.
The launch of Gyrolab Bioaffy confirms the company’s earlier claim
that Gyros technology platform allows development of
multi-application instruments. Both Gyrolab Bioaffy and Gyrolab
MALDI CD microlaboratories can be run on the same workstation.
For further information, visit
www.gyros.com.
Meetings with Gyros personnel during the Drug Discovery and
Technology event can be arranged through Sue Cresswell, Marketing
Communications.
Sue Cresswell, Marketing Communications
Tel: +46 (0)8 54472620
Mobile: +46 (0)70 551 9520
Email:
sue.cresswell@gyros.com
|
|
